Peptide Drug Discovery Market Size & Share Analysis - Growth Trends & Forecast (2025 - 2030)

The Peptide Drug Discovery Market Report is Segmented by Drug Type (Therapeutic Peptides and Vaccine Peptides), by Technology (Solid-Phase Peptide Synthesis, Solution-Phase Peptide Synthesis, Recombinant Technology, and Other Technologies), by Route of Administration (Parenteral, Oral, and Other Routes of Administration), by Application (Neurological Disorders, Infectious Diseases, Metabolic Disorders, Oncology, Autoimmune Diseases, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Peptide Drug Discovery Market Size & Share Analysis - Growth Trends & Forecast (2025 - 2030)

Peptide Drug Discovery Market Size

Peptide Drug Discovery Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 546.5 Million
Market Size (2030) USD 755.80 Million
CAGR (2025 - 2030) 6.70 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Peptide Drug Discovery Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Peptide Drug Discovery Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Peptide Drug Discovery Market Analysis

The Peptide Drug Discovery Market size is estimated at USD 546.5 million in 2025, and is expected to reach USD 755.80 million by 2030, at a CAGR of 6.70% during the forecast period (2025-2030).

The peptide drug discovery market is witnessing growth, primarily fueled by the rising prevalence of cancer, multiple sclerosis, respiratory diseases, HIV infection, and cardiovascular diseases, among others. For instance, in January 2023, data published by the American Cancer Society revealed that over 1.9 million total new cancer cases were diagnosed in the United States in 2023. Additionally, the World Health Organization (WHO), in February 2024, stated that about one in five individuals develop cancer in their lifetime globally. These data collectively indicate the significant burden of cancer disease around the globe and underscore the critical need for advancements in peptide drug discovery to develop novel peptide-based drugs for cancer therapy.

Moreover, the growing burden of cardiovascular diseases is expected to drive the growth of peptide drug discovery for the development of effective peptide-based cardiovascular therapeutics, further fueling the market growth. For instance, in September 2023, the British Heart Foundation reported that approximately 620 million people globally were living with heart and circulatory diseases, with peripheral arterial disease and stroke being the most prevalent conditions. Moreover, this figure reached around 640 million in January 2025. Collectively, these statistics underscore the importance of peptide therapeutics, owing to their high efficacy and safety in the treatment of chronic diseases. This, in turn, is expected to drive the growth of the peptide drug discovery market over the forecast period.

In addition, peptide drug development has witnessed moderate growth in recent years, driven by advancements in production, modification, and analytic technologies in peptide production. Notably, the integration of AI into these processes has been a significant catalyst. For instance, in January 2025, Pepticom Ltd. secured USD 6.6 million in its Series A1 funding round, a move anticipated to expedite AI-driven peptide drug discovery. Through this funding, Pepticom Ltd. is enhancing its unique biocomputational AI software to optimize the process of peptide drug discovery with reduced development cost and risk. Further emphasizing the trend, Fujitsu launched the "Biodrug Design Accelerator" in May 2023, a platform designed to streamline peptide drug discovery. This platform bolsters the Design Make Test Analyze (DMTA) cycle, promoting centralized data management, visualization, and enhanced collaboration among researchers.

While the peptide drug discovery market outlook appears promising, challenges remain. The complex synthesis and purification processes lead to elevated manufacturing costs, hindering affordability and widespread adoption. Furthermore, concerns regarding the stability and bioavailability of peptide drugs pose additional hurdles to the market's growth.

North America is Expected to Dominate the Peptide Drug Discovery Market

North America is expected to hold a significant share of the global peptide drug discovery market. Key drivers include the strong presence of market players, extensive research and development activities, advanced R&D infrastructure, and an increase in strategic initiatives such as acquisitions by major companies in the region. For example, in December 2024, AbbVie Inc. announced the acquisition of Nimble Therapeutics, a company specializing in the discovery of oral peptide-based medicines. This acquisition aims to enhance AbbVie's capabilities in the rapid discovery and optimization of peptide therapeutics.

Additionally, increased funding activities and collaborations between pharmaceutical firms and Contract Research Organizations (CROs) bolster the market's growth prospects. For instance, in March 2023, Arch Biopartners Inc. received USD 4 million in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). This funding supports the development of the LSALT peptide (Metablok) program and future drug approvals. The LSALT peptide, the leading drug candidate of the company, targets acute inflammation injuries in the lungs, kidneys, and liver. NRC IRAP also provides advisory services to advance the program, driving the growth of the peptide drug discovery market in the North America region.

Furthermore, the growing burden of chronic, infectious, and respiratory diseases in North America fuels the market's growth. For instance, in September 2024, the Asthma and Allergy Foundation of America stated that approximately 28 million Americans were affected by asthma, with a notable rise in prevalence among women and adults over 65. Additionally, in December 2024, The New York City Department of Health and Mental Hygiene reported a 7.6 percent increase in new HIV infections, totaling 1,686 cases in the year 2023 in New York City. These factors mentioned above highlight the growing disease burden, emphasizing the need for peptide drug discovery to develop innovative therapeutics for these conditions.

Peptide Drug Discovery Market - Growth Rate by Region

Peptide Drug Discovery Industry Overview

The peptide drug discovery market is moderately competitive in nature. Several leading and local companies are focusing on investment in R&D activities to gain a competitive edge. Some companies hold strong strategic positions in the market, such as CPC Scientific Inc., JPT Peptide Technologies, and GenScript Biotech Corporation, owing to their wide presence in many countries across the globe. The competitive landscape includes an analysis of key companies that include IRBM S.p.a., Creative Peptides, Interprotein Corporation, Pepscan, UCB S.A., Pepticom Ltd., PeptiDream Inc., Creative Biolabs, Inc., MeSCue-Janusys Inc., and among others.

Peptide Drug Discovery Market Leaders

  1. CPC Scientific Inc.

  2. JPT Peptide Technologies

  3. GenScript Biotech Corporation

  4. IRBM S.p.a.

  5. PeptiDream Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Peptide Drug Discovery Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Peptide Drug Discovery Market News

  • May 2024: Novartis Pharma AG announced a peptide discovery partnership with Peptidream Inc., valued at up to USD 2.71 billion. As part of the multi-program agreement, PeptiDream will use its Peptide Discovery Platform System (PDPS) technology to identify and optimize macrocyclic peptides for targets specified by Novartis Pharma AG.
  • June 2023: IRBM S.p.A., a well-known contract research organization, signed an agreement with Merck & Co., Inc. (MSD) to strengthen their partnership in peptide therapeutics development. This agreement allows IRBM to integrate its expertise in peptide design and synthesis with Merck's capabilities, focusing on the development of innovative peptide-based therapeutics.

Peptide Drug Discovery Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases
    • 4.2.2 Rising Investment for Peptide Drug Discovery and Development
    • 4.2.3 Growing Collaboration Between Pharmaceutical Companies and CROs for Peptide Development
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated R&D
    • 4.3.2 Complex Manufacturing Process
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value)

  • 5.1 By Drug Type
    • 5.1.1 Therapeutic Peptides
    • 5.1.2 Vaccine Peptides
  • 5.2 By Technology
    • 5.2.1 Solid-Phase Peptide Synthesis
    • 5.2.2 Solution-Phase Peptide Synthesis
    • 5.2.3 Recombinant Technology
    • 5.2.4 Other Technologies (Peptide Microarrays and Hybrid Techniques)
  • 5.3 By Route of Administration
    • 5.3.1 Parenteral
    • 5.3.2 Oral
    • 5.3.3 Other Routes of Administration
  • 5.4 By Application
    • 5.4.1 Neurological Disorders
    • 5.4.2 Infectious Diseases
    • 5.4.3 Metabolic Disorders
    • 5.4.4 Oncology
    • 5.4.5 Autoimmune Diseases
    • 5.4.6 Other Applications (Gastrointestinal Disorder, Pain Management, Reproductive Disorders, and Respiratory Disorders)
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 CPC Scientific Inc.
    • 6.1.2 IRBM
    • 6.1.3 Creative Peptides
    • 6.1.4 Interprotein Corporation
    • 6.1.5 Pepscan
    • 6.1.6 UCB S.A
    • 6.1.7 Pepticom Ltd.
    • 6.1.8 PeptiDream Inc.
    • 6.1.9 Creative Biolabs, Inc.
    • 6.1.10 MeSCue-Janusys Inc.
    • 6.1.11 JPT Peptide Technologies
    • 6.1.12 GenScript Biotech Corporation
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Peptide Drug Discovery Industry Segmentation

Peptide drug discovery involves developing peptides into therapeutic drugs through extensive preclinical and clinical evaluations. This involves modifying peptides biologically or synthetically to improve their pharmacological properties. Peptide therapeutics offer several advantages over small-molecule drugs, including higher biological activity, greater specificity, lower toxicity, fewer drug interactions, and enhanced receptor binding affinity. These factors are driving the growth of the peptide drug discovery market.

The peptide drug discovery market is segmented into drug type, technology, route of administration, application, and geography. By drug type, the market is segmented into therapeutic peptides and vaccine peptides. By technology, the market is segmented into solid-phase peptide synthesis, solution-phase peptide synthesis, recombinant technology, and other technologies (peptide microarrays and hybrid techniques, among others). By route of administration, the market is segmented into parenteral, oral, and other route of administration (topical, transdermal, and nasal, among others). By application, the market is segmented into neurological disorders, infectious diseases, metabolic disorders, oncology, autoimmune diseases, and other applications (gastrointestinal disorders, pain management, reproductive disorders, and respiratory disorders). By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts have been done on the basis of revenue (USD).

By Drug Type Therapeutic Peptides
Vaccine Peptides
By Technology Solid-Phase Peptide Synthesis
Solution-Phase Peptide Synthesis
Recombinant Technology
Other Technologies (Peptide Microarrays and Hybrid Techniques)
By Route of Administration Parenteral
Oral
Other Routes of Administration
By Application Neurological Disorders
Infectious Diseases
Metabolic Disorders
Oncology
Autoimmune Diseases
Other Applications (Gastrointestinal Disorder, Pain Management, Reproductive Disorders, and Respiratory Disorders)
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Peptide Drug Discovery Market Research FAQs

How big is the Peptide Drug Discovery Market?

The Peptide Drug Discovery Market size is expected to reach USD 546.5 million in 2025 and grow at a CAGR of 6.70% to reach USD 755.80 million by 2030.

What is the current Peptide Drug Discovery Market size?

In 2025, the Peptide Drug Discovery Market size is expected to reach USD 546.5 million.

Who are the key players in Peptide Drug Discovery Market?

CPC Scientific Inc., JPT Peptide Technologies, GenScript Biotech Corporation, IRBM S.p.a. and PeptiDream Inc. are the major companies operating in the Peptide Drug Discovery Market.

Which is the fastest growing region in Peptide Drug Discovery Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Peptide Drug Discovery Market?

In 2025, the North America accounts for the largest market share in Peptide Drug Discovery Market.

What years does this Peptide Drug Discovery Market cover, and what was the market size in 2024?

In 2024, the Peptide Drug Discovery Market size was estimated at USD 509.88 million. The report covers the Peptide Drug Discovery Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Peptide Drug Discovery Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Peptide Drug Discovery Industry Report

Statistics for the 2025 Peptide Drug Discovery market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Peptide Drug Discovery analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.